Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Friday.

A number of other equities research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. ValuEngine raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Cantor Fitzgerald set a $28.00 price target on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, May 9th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $22.50.

Aquinox Pharmaceuticals (NASDAQ AQXP) traded up 2.47% during midday trading on Friday, reaching $14.92. 45,161 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $14.46 and a 200-day moving average of $15.62. The stock’s market cap is $349.47 million. Aquinox Pharmaceuticals has a 12 month low of $8.04 and a 12 month high of $19.97.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its earnings results on Tuesday, May 9th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.15. During the same quarter in the previous year, the company earned ($0.39) earnings per share. On average, equities research analysts predict that Aquinox Pharmaceuticals will post ($2.05) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/06/aquinox-pharmaceuticals-inc-nasdaqaqxp-upgraded-by-bidaskclub-to-hold.html.

In other Aquinox Pharmaceuticals news, insider David Main sold 15,625 shares of Aquinox Pharmaceuticals stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $13.26, for a total transaction of $207,187.50. Following the transaction, the insider now directly owns 77,530 shares of the company’s stock, valued at $1,028,047.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 2.70% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of AQXP. Bank of New York Mellon Corp increased its position in Aquinox Pharmaceuticals by 16.5% in the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock valued at $327,000 after buying an additional 3,299 shares during the period. Alps Advisors Inc. increased its position in Aquinox Pharmaceuticals by 4.7% in the second quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock valued at $297,000 after buying an additional 939 shares during the period. Investment Centers of America Inc. acquired a new position in Aquinox Pharmaceuticals during the first quarter valued at approximately $172,000. Finally, Geode Capital Management LLC increased its position in Aquinox Pharmaceuticals by 10.0% in the first quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock valued at $2,028,000 after buying an additional 11,035 shares during the period. 98.32% of the stock is currently owned by hedge funds and other institutional investors.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.